CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

Company Overview

CASI Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide.

The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers. In addition to famitinib, CASI is advancing an immuno-oncology portfolio that includes checkpoint inhibitors and novel immune modulators designed to enhance antitumor responses. Preclinical programs focus on next‐generation molecules with potential applications in both oncology and inflammatory disorders, building on the company’s proprietary discovery platform.

Founded by a team of biotech entrepreneurs and scientists, CASI Pharmaceuticals is headquartered in Beijing, with research and development operations in Shanghai and a presence in North America to support global clinical activities. The company has established strategic partnerships with academic institutions and contract research organizations to accelerate its clinical trials and expand its pipeline. CASI’s leadership team comprises industry veterans with extensive experience in drug development and regulatory affairs, guiding the company through key milestones as it pursues regulatory approvals and commercial readiness.

Key Stats

• Today's Range: $1.78 to $1.94
• 50-Day Range: $1.29 to $2.47
• 52-Week Range: $1.09 to $7.50
• Volume: 40,652 shs
• Average Volume: 471,999 shs
• Market Capitalization: $22.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

CASI Pharmaceuticals Stock Analysis - MarketRank™

CASI Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 434th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

CASI Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

CASI Pharmaceuticals has a consensus price target of $4.00, representing about 115.1% upside from its current price of $1.86.

Amount of Analyst Coverage

CASI Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CASI Pharmaceuticals is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CASI Pharmaceuticals is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CASI Pharmaceuticals has a P/B Ratio of 15.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.50% of the float of CASI Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CASI Pharmaceuticals has recently decreased by 18.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CASI Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CASI Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.50

Percentage of Shares Shorted

7.50% of the float of CASI Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CASI Pharmaceuticals has recently decreased by 18.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.23% of the stock of CASI Pharmaceuticals is held by institutions.

CASI Stock Analysis - Frequently Asked Questions

How have CASI shares performed this year?

CASI Pharmaceuticals' stock was trading at $2.83 on January 1st, 2025. Since then, CASI shares have decreased by 34.3% and is now trading at $1.86.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals Inc. (NASDAQ:CASI) issued its quarterly earnings results on Friday, August, 29th. The biotechnology company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.39. The biotechnology company had revenue of $4.18 million for the quarter, compared to analysts' expectations of $6.28 million. CASI Pharmaceuticals had a negative net margin of 148.55% and a negative trailing twelve-month return on equity of 972.55%.

When did CASI Pharmaceuticals' stock split?

Shares of CASI Pharmaceuticals reverse split on the morning of Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/29/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CASI
• CIK: 895051
• Web: www.casipharmaceuticals.com
• Phone: 861065086063
• Fax: 301-315-2437
• Employees: 180
• Year Founded: 1991

Price Target and Rating

• Average Price Target for CASI Pharmaceuticals: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +115.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.26 million
• Net Margins: -148.55%
• Pretax Margin: -137.90%
• Return on Equity: -972.55%
• Return on Assets: -99.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.48
• Quick Ratio: 0.39

Sales & Book Value

• Annual Sales: $28.54 million
• Price / Sales: 0.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 15.50

Miscellaneous

• Outstanding Shares: 12,300,000
• Free Float: 9,687,000
• Market Cap: $22.88 million
• Optionable: Optionable
• Beta: 0.69